Soleno therapeutics inc (SLNO)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Jun'14Mar'14
Cash flows from operating activities:
Net loss

-5,858

-14,625

889

-10,008

-7,030

263

-2,736

-7,058

-3,804

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-2,887

-2,613

-2,750

-3,513

-3,189

-2,844

-3,294

1,881

-11,651

-2,793

-834

Loss from discontinued operations

-

-

-

-

-

-130

-427

-423

-514

-544

-1,294

-913

-842

-

-

-

-

-

-

-

-

-

-

Loss from continuing operations

-

-

-

-

-

393

-2,309

-6,635

-3,290

-4,199

-2,492

-3,056

-2,045

-

-

-

-

-

-

-

-

-

-

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

489

490

490

489

489

490

490

491

492

582

459

451

119

17

-44

25

20

-48

28

16

15

7

7

Noncash lease expense

68

-

-

-

110

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

392

295

153

129

248

532

212

178

341

131

204

405

140

-

-

-

-

-

-

-

-

-

-

Board fees paid with common stock

-

-

-

-

-

-

61

54

82

83

82

68

45

24

0

0

0

-

-

-

-

-

-

Stock-based compensation expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

218

136

-

144

201

401

5

11

Change in fair value of stock warrants

-3,413

7,894

-7,116

4,267

1,919

-2,071

-1,543

3,255

-163

656

-131

91

69

-

-

-

-

-

-

-

-

-

-246

Change in fair value of contingent consideration

584

-128

28

183

206

-22

228

-67

428

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of contingent consideration

-

-

-

-

-

-

-

-

-

-

-

-

5

-

-

-

19

-

0

0

0

-

-

Loss on disposition of property & equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-8

Inducement charge for Series C warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0

0

0

3,050

-

-

Change in fair value of common stock warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-201

48

-1,170

-

-72

-4,925

6,174

-

-

Non-cash expense of issuing shares to Aspire Capital

-

-

-

-

-

-

-

-

-

0

0

0

602

0

0

0

0

-

-

-

-

-

-

Operating loss on minority interest investment

-

0

-123

-165

-190

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense relating to warrants and convertible promissory notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

670

388

Change in operating assets and liabilities:
Accounts receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2

-29

31

-

82

4

8

19

-150

Inventory

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

568

102

-

98

72

97

-

-

Other receivables

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

41

Prepaid expenses, other current assets and other assets

161

144

-96

-132

74

202

-47

-175

80

198

-100

-16

15

-139

64

-61

49

-50

-86

52

7

23

77

Due from related party

-

-9

-9

-54

8

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

1,485

260

-5

482

324

-363

264

-61

409

-41

273

163

-204

-412

258

-549

627

-977

141

202

199

187

31

Accrued compensation

55

-

-

-

-92

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued clinical trial site costs

847

-

-

-

188

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities

10

-

-

-

-117

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other liabilities

-157

-

-

-

-40

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued compensation and other liabilities

-

-

-

-

-

-

278

141

-252

-4

190

-215

-49

-

-

-

-

-

-

-

-

-

-

Accrued compensation and other current liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

207

-56

-317

-

103

502

115

-48

94

Other long-term liabilities

-

-

-

-

-

-

-

-

-

-20

5

-9

-16

-11

-12

-8

72

0

0

0

0

-

-

Net cash used in continuing operating activities

-

-

-

-

-

-3,548

-2,272

-2,469

-2,033

-2,169

-1,310

-2,091

-1,349

-

-

-

-

-

-

-

-

-1,157

-509

Net cash used in discontinued operating activities

-

-

-

-

-

-188

-405

-281

-487

-563

-733

-901

-834

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-5,659

-5,076

-4,719

-3,893

-3,687

-3,736

-2,677

-2,750

-2,520

-2,732

-2,043

-2,992

-2,183

-2,688

-2,786

-4,039

-3,984

-3,378

-2,861

-2,251

-1,809

-

-

Proceeds from sale of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

4

Purchases of property and equipment

-

5

0

6

10

-

-

-

-

-

-

-

-

-7

2

1

19

-3

32

15

1

-

-

Net cash provided by (used in) continuing investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3

4

Net cash used in discontinued investing activities

-

-

-

-

-

-

-

-

-

0

717

3

-4

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

-

103

441

-6

-10

-

-

-

-

15

143

0

-4

0

0

-20

-19

-31

-1,258

-30

-1

-

-

Cash flows from financing activities:
Principal paid on finance lease liabilities

4

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of common stock options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0

0

282

12

-

-

Proceeds from issuance of common stock

-

-

-

-

-

-

-

-

-

0

0

0

10,000

-70

0

70

0

-

-

-

-

-

-

Cash paid for the issuance of common stock and common stock warrants

-

-

-

-

-

-

-

-

112

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of credit line

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0

0

0

102

-

-

Net proceeds from issuance of Convertible Preferred

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

Cash paid for the issuance cost of common stock and common stock warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

45

0

0

530

-

-

Net cash provided by continuing financing activities

-

-

-

-

-

-

-

-

-112

13,945

0

0

10,000

-

-

-

-

-

-

-

-

-

-

Net cash provided by discontinued financing activities

-

-

-

-

-

0

700

425

400

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in financing activities

-4

-

-

-

-

16,302

700

537

288

14,170

0

0

10,000

0

5,698

70

5,000

4,184

1,309

282

3,382

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,688

2,913

-3,990

997

774

-2,810

-1,999

1,572

444

-505

Net decrease in cash and cash equivalents

-5,663

9,508

-4,278

-3,899

-3,697

12,392

-1,982

-2,214

-2,232

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash, cash equivalents and restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

7,813

-

-

-

-

-

-

-

-

-

-

Net increase in cash and cash equivalents included in current assets held for sale

-

-

-

-

-

-

-372

-94

-2

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental disclosures of non-cash investing and financing information
Conversion of preferred to common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

555

1,665

-

-

-

-

-

-

Patent costs included in Accrued liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-150

450

0

-

-

Issuance of common stock in Essentialis acquisition

-

-

-

-

-

-

-

-

-

-1,518

0

1,518

17,246

0

0

0

0

0

0

112

0

-

-

Contingent consideration of Essentialis acquisition

-

-

-

-

-

-

-

-

-

1,500

0

-1,500

2,590

-

-

-

-

-

-

-

-

-

-

Accrued liability for cost of issuing common stock

-

-

-

-

-

-

-

-

91

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Preferred convertible stock transaction costs included in Accounts Payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

131

-

-

Fixed asset purchases in accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

Costs of Essentialis acquisition included in accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

Contingent consideration of Essentialis acquisition

-

-

-

-

-

-

-

-

-

1,500

0

-1,500

2,590

0

0

0

0

-

-

-

-

-

-

Reduction in initial public offering costs payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

45

-

-

Continuing Operations [Member]
Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

12,752

-2,277

-2,358

-2,145

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Discontinued Operations [Member]
Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-360

295

144

-87

-

-

-

-

-

-

-

-

-

-

-

-

-

-